{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:11:15Z","timestamp":1784956275283,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s13760-023-02187-0","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T05:14:48Z","timestamp":1674191688000},"page":"375-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current management of myasthenia gravis in Belgium: a single-center experience"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-4716","authenticated-orcid":false,"given":"Rudy","family":"Mercelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alonso-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Schil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"2","key":"2187_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJ Verschuuren","year":"2022","unstructured":"Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V (2022) Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 21(2):189\u2013202. https:\/\/doi.org\/10.1016\/S1474-4422(21)00463-4","journal-title":"Lancet Neurol"},{"issue":"2","key":"2187_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 21(2):176\u2013188. https:\/\/doi.org\/10.1016\/S1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"issue":"10","key":"2187_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.nmd.2020.08.355","volume":"30","author":"E Westerberg","year":"2020","unstructured":"Westerberg E, Punga AR (2020) Mortality rates and causes of death in Swedish Myasthenia Gravis patients. Neuromuscul Disord 30(10):815\u2013824. https:\/\/doi.org\/10.1016\/j.nmd.2020.08.355","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2187_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E et al (2022) Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol 9(2):122\u2013131. https:\/\/doi.org\/10.1002\/acn3.51492","journal-title":"Ann Clin Transl Neurol"},{"key":"2187_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/WNL.55.1.16","journal-title":"Neurology"},{"key":"2187_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1749-6632.2012.06789.x","volume":"1274","author":"A Vincent","year":"2012","unstructured":"Vincent A et al (2012) Antibodies identified by cell-based assays in myasthenia gravis and associated diseases. Ann NY Acad Sci 1274:92\u201398. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06789.x","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"2187_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/mus.21853","volume":"43","author":"R Mercelis","year":"2011","unstructured":"Mercelis R, Merckaert V (2011) Diagnostic utility of stimulated single-fiber electromyography of the orbicularis oculi muscle in patients with suspected ocular myasthenia. Muscle Nerve 43(2):168\u2013170. https:\/\/doi.org\/10.1002\/mus.21853","journal-title":"Muscle Nerve"},{"issue":"2","key":"2187_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/mus.27120","volume":"63","author":"DB Sanders","year":"2021","unstructured":"Sanders DB, Raja SM, Guptill JT, Hobson-Webb LD, Juel VC, Massey JM (2021) The Duke myasthenia gravis clinic registry: I. Description and demographics. Muscle Nerve 63(2):209\u2013216. https:\/\/doi.org\/10.1002\/mus.27120","journal-title":"Muscle Nerve"},{"key":"2187_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.605902","author":"A Evoli","year":"2020","unstructured":"Evoli A, Iorio R (2020) Controversies in Ocular Myasthenia Gravis. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.605902","journal-title":"Front Neurol"},{"issue":"6","key":"2187_CR10","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2021","unstructured":"Lehnerer S et al (2021) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol 269(6):3050. https:\/\/doi.org\/10.1007\/s00415-021-10891-1","journal-title":"J Neurol"},{"key":"2187_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of <scp>MG-ADL<\/scp> in myasthenia gravis clinical research and care. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"issue":"23","key":"2187_CR12","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","volume":"89","author":"C Barnett","year":"2017","unstructured":"Barnett C, Bril V, Kapral M, Kulkarni AV, Davis AM (2017) Myasthenia gravis impairment index. Neurology 89(23):2357\u20132364. https:\/\/doi.org\/10.1212\/WNL.0000000000004676","journal-title":"Neurology"},{"key":"2187_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25720","author":"A Abraham","year":"2017","unstructured":"Abraham A, Breiner A, Barnett C, Katzberg HD, Bril V (2017) The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.25720","journal-title":"Muscle Nerve"},{"issue":"12","key":"2187_CR14","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C (2020) Patient-acceptable symptom states in myasthenia gravis. Neurology 95(12):e1617\u2013e1628. https:\/\/doi.org\/10.1212\/WNL.0000000000010574","journal-title":"Neurology"},{"key":"2187_CR15","doi-asserted-by":"publisher","first-page":"116830","DOI":"10.1016\/j.jns.2020.116830","volume":"414","author":"R Anil","year":"2020","unstructured":"Anil R et al (2020) Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry \u2013 The EXPLORE-MG registry. J Neurol Sci 414:116830. https:\/\/doi.org\/10.1016\/j.jns.2020.116830","journal-title":"J Neurol Sci"},{"key":"2187_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24438","author":"T Imai","year":"2014","unstructured":"Imai T et al (2014) Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.24438","journal-title":"Muscle Nerve"},{"key":"2187_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10264-0","author":"I Lotan","year":"2020","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I (2020) Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10264-0","journal-title":"J Neurol"},{"issue":"4","key":"2187_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB et al (2016) International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"2187_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","volume":"369","author":"L Gotterer Do","year":"2016","unstructured":"Gotterer Do L, Li Y (2016) Maintenance immunosuppression in myasthenia gravis. J Neurol Sci 369:294\u2013304. https:\/\/doi.org\/10.1016\/j.jns.2016.08.057","journal-title":"J Neurol Sci"},{"issue":"1","key":"2187_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CND.0000000000000133","volume":"18","author":"KL Jack","year":"2016","unstructured":"Jack KL, Koopman WJ, Hulley D, Nicolle MW (2016) A Review of Azathioprine-Associated hepatotoxicity and myelosuppression in myasthenia gravis. J Clin Neuromuscul Dis 18(1):12\u201320. https:\/\/doi.org\/10.1097\/CND.0000000000000133","journal-title":"J Clin Neuromuscul Dis"},{"key":"2187_CR21","doi-asserted-by":"publisher","first-page":"116734","DOI":"10.1016\/j.jns.2020.116734","volume":"412","author":"PJ Lorenzoni","year":"2020","unstructured":"Lorenzoni PJ, Kay CSK, Zanlorenzi MF, Ducci RDP, Werneck LC, Scola RH (2020) Myasthenia gravis and azathioprine treatment: Adverse events related to thiopurine S-methyl-transferase (TPMT) polymorphisms. J Neurol Sci 412:116734. https:\/\/doi.org\/10.1016\/j.jns.2020.116734","journal-title":"J Neurol Sci"},{"issue":"3","key":"2187_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/ene.12329","volume":"21","author":"EG Pedersen","year":"2014","unstructured":"Pedersen EG et al (2014) Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol 21(3):454\u2013458. https:\/\/doi.org\/10.1111\/ene.12329","journal-title":"Eur J Neurol"},{"issue":"6","key":"2187_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB et al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71(6):400\u2013406. https:\/\/doi.org\/10.1212\/01.wnl.0000312374.95186.cc","journal-title":"Neurology"},{"issue":"10","key":"2187_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology 89(10):1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"},{"key":"2187_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000013121","author":"RJ Nowak","year":"2021","unstructured":"Nowak RJ et al (2021) Phase 2 Trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG Study. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000013121","journal-title":"Neurology"},{"issue":"2","key":"2187_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mus.23508","volume":"47","author":"JT Guptill","year":"2013","unstructured":"Guptill JT et al (2013) A retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve 47(2):170\u2013176. https:\/\/doi.org\/10.1002\/mus.23508","journal-title":"Muscle Nerve"},{"issue":"1","key":"2187_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1155\/2012\/874680","volume":"1","author":"A Jayam Trouth","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J (2012) Myasthenia gravis: a review. Autoimmun Dis 1(1):10. https:\/\/doi.org\/10.1155\/2012\/874680","journal-title":"Autoimmun Dis"},{"key":"2187_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.02.010","author":"A Marx","year":"2015","unstructured":"Marx A et al (2015) Thymoma related myasthenia gravis in humans and potential animal models. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2015.02.010","journal-title":"Exp Neurol"},{"issue":"6","key":"2187_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375(6):511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1602489","journal-title":"N Engl J Med"},{"key":"2187_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jneuroim.2008.07.012","volume":"201\u2013202","author":"L Maggi","year":"2008","unstructured":"Maggi L et al (2008) Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol 201\u2013202:237\u2013244. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.07.012","journal-title":"J Neuroimmunol"},{"issue":"9","key":"2187_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/(SICI)1097-4598(199609)19","volume":"19","author":"DB Sanders","year":"1996","unstructured":"Sanders DB, St\u00e5lberg EV (1996) AAEM minimonograph 25: Single-fiber electromyography. Muscle Nerve 19(9):1069\u20131083. https:\/\/doi.org\/10.1002\/(SICI)1097-4598(199609)19","journal-title":"Muscle Nerve"},{"issue":"7","key":"2187_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S1388-2457(00)00307-2","volume":"111","author":"L Padua","year":"2000","unstructured":"Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P (2000) SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol 111(7):1203\u20131207","journal-title":"Clin Neurophysiol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-023-02187-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T20:12:30Z","timestamp":1744143150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-023-02187-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2187"],"URL":"https:\/\/doi.org\/10.1007\/s13760-023-02187-0","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"26 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of the Antwerp University Hospital in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Rudy Mercelis received consultancy fees of Alexion and ArgenX and Alicia Alonso-Jim\u00e9nez has participated in advisory boards for Alexion and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}